* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data
Trend
Dec21
Dec22
Dec23
Gross Profit
6.20
0.60
0.42
ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
Dec21
Jun22
Dec22
Jun23
Dec23
Gross Profit
-
0.50
0.13
0.09
0.33
Competitive Comparison of ImmuneOnco Biopharmaceuticals (Shanghai)'s Gross Profit
For the Biotechnology subindustry, ImmuneOnco Biopharmaceuticals (Shanghai)'s Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImmuneOnco Biopharmaceuticals (Shanghai)'s Gross Profit Distribution in the Biotechnology Industry
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.42 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
(Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
ImmuneOnco Biopharmaceuticals (Shanghai) had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage
ImmuneOnco Biopharmaceuticals (Shanghai) Gross Profit Related Terms
Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Business Description
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01541 has been successfully added to your